Skip to main content
Scienza Health
INSIGHTS

Clinical intelligence for care leaders.

Voice Biomarkers

Speech Biomarkers and Disease Detection

This article discusses how voice analysis can screen for diseases. [Speech biomarkers](/blog/speech-biomarkers-disease-detection), measurable characteristics within voice, are used by [GIA](/gia) to provide a rapid and accessible screening tool. Powered by [digitalhumanOS™](/platform), this approach offers a non-invasive method for detecting potential health issues in PAC/LTC residents, enabling earlier intervention and improved patient outcomes. By analyzing subtle changes in voice, we can uncover hidden insights into overall well-being.

David Kaiser · 3 min readRead Article →
Voice Biomarkers

Voice AI Detects Depression in PAC Patients

This article discusses voice AI's ability to screen for depression in post-acute care (PAC) patients. [GIA](/gia), powered by [digitalhumanOS™](/platform), screens for depression using voice AI with 81.6% accuracy. Identifying depression early is important for effective treatment and improved quality of life. [GIA](/gia) analyzes subtle vocal cues indicative of depression, enabling clinicians to provide timely support and intervention. [GIA](/gia) is FDA-registered.

David Kaiser · 3 min readRead Article →
Voice Biomarkers

Acoustic Signs of Cognitive Decline via Voice

This article discusses how voice AI can detect acoustic signs of [cognitive decline](/screening/cognitive-decline). [GIA](/gia) uses voice analysis to identify acoustic signs of cognitive decline with 70.8% accuracy. Cognitive decline is a significant concern, particularly within PAC/LTC settings. Early detection is critical for implementing supportive care strategies and maximizing quality of life. By analyzing subtle changes in speech patterns using [digitalhumanOS™](/platform), [GIA](/gia) helps clinicians identify at-risk individuals, enabling proactive care and improved outcomes. [GIA](/gia) screens for 46 conditions, does not diagnose.

David Kaiser · 3 min readRead Article →
Voice Biomarkers

How Parkinson's Changes Speech Biomarkers

This article discusses how Parkinson's Disease (PD) significantly impacts speech and how voice analysis can help in early detection. [GIA](/gia), powered by [digitalhumanOS™](/platform), uses voice analysis to identify these changes with high accuracy (AUC 0.97). By analyzing vocal features, [GIA](/gia) can assist in the early detection of PD, enabling prompt intervention and improved management of the disease symptoms. This proactive approach can significantly enhance the quality of life for individuals with Parkinson's. [GIA](/gia) screens, does not diagnose. [GIA](/gia) is FDA-registered.

David Kaiser · 3 min readRead Article →
Voice Biomarkers

Voice Biomarkers for Alzheimer's Early Detection

This article discusses using voice biomarkers to screen for early signs of Alzheimer's disease. [GIA](/gia) screens for subtle speech changes linked to Alzheimer's, potentially years before traditional diagnosis, by analyzing vocal characteristics using [digitalhumanOS](/technology). [GIA](/gia) screens, does not diagnose. Early detection of Alzheimer's disease is important for implementing supportive care strategies and supporting earlier clinical intervention. By analyzing vocal characteristics, [GIA](/gia) offers a non-invasive method for early screening, enabling proactive care and improved patient outcomes.

David Kaiser · 3 min readRead Article →
Voice Biomarkers

Speech Patterns Reveal Anxiety in LTC Residents

This article discusses [anxiety screening](/screening/anxiety) in long-term care (LTC) using voice analysis. [GIA](/gia) screens for anxiety by analyzing speech patterns with 77.5% accuracy, helping clinicians identify at-risk individuals and enabling proactive care for LTC residents. Identifying anxiety early is important for providing appropriate support and improving quality of life. [GIA](/gia), powered by [digitalhumanOS](/platform), screens using voice analysis to detect speech patterns indicative of anxiety.

David Kaiser · 3 min readRead Article →
Clinical AI

The Cognitive Screening Gap in Wellness Visits

This article discusses the gap in [cognitive screening](/screening/cognitive-decline) during Medicare Annual Wellness Visits (AWVs) and a digital [GIA](/gia) solution. While cognitive impairment detection is a required component of the AWV, fewer than half of physicians consistently incorporate these screenings. This leaves a significant portion of patients potentially undiagnosed. Data from 12.3M patients and 27B clinical events supports the need for better screening tools.

David Kaiser · 3 min readRead Article →
Clinical AI

4 in 10 Cognitive Referrals Are False Positives

This article discusses how to reduce false positive cognitive referrals to neurologists. Currently, 4 in 10 cognitive referrals from primary care physicians are false positives, contributing to longer wait times and exacerbating neurologist shortages. Neurologists face growing patient loads, administrative burdens, and pressure to deliver optimal care, with 45% reporting burnout. This is compounded by a significant influx of referrals that don't require specialized expertise, contributing to wait times averaging over 45 days. There has to be a better way to focus your expertise where it’s most needed.

David Kaiser · 3 min readRead Article →
Clinical AI

1 Geriatrician per 5,000 Patients Over 65

This article discusses the challenges geriatricians face due to workforce shortages and increasing demands for [cognitive assessments](/screening/cognitive-decline), and how technology can help. There is approximately one geriatrician for every 5,000 Americans aged 65 and older, far from the recommended 1:750 ratio. This shortage, coupled with the CMS requirement for [cognitive decline screening](/screening/cognitive-decline) for Medicare patients 65+, creates immense pressure.

David Kaiser · 3 min readRead Article →
Clinical AI

Voice-Based Parkinson's Detection Accuracy

This article discusses the accuracy of voice-based [Parkinson's](/screening/parkinsons-disease) detection using [GIA](/gia)™ in clinical settings. [GIA](/gia)™ screens for Parkinson's with an Area Under the Curve (AUC) of 0.97. GIA™ uses speech biomarkers from a brief conversation, providing clinicians with objective data to support their judgment and enable timely intervention and care planning. This approach aims to reduce the burden on clinical staff while improving the quality of care for residents. By identifying potential cases early, facilities can optimize resource allocation and potentially slow the progression of the disease through targeted therapies and support. GIA screens for 46 conditions, including [Depression](/screening/depression), [PTSD](/screening/ptsd), and [Anxiety](/screening/anxiety).

David Kaiser · 3 min readRead Article →
Clinical AI

Zero-Staff Cognitive Screening for PAC

This article discusses how to screen post-acute care residents for [cognitive decline](/screening/cognitive-decline) without staff involvement. [GIA](/gia), a [Digital Human](/technology), offers zero staff time cognitive screening, enhancing resident care and addressing staffing challenges.

David Kaiser · 3 min readRead Article →
Clinical AI

PointClickCare EHR Cognitive Screening

This article discusses integrating [cognitive screening](/screening) into [PointClickCare EHR](/integrations) to improve the identification and management of [cognitive decline](/screening/cognitive-decline). Scienza Health's [GIA](/gia), a voice-enabled screening tool, is now available in the PointClickCare marketplace, offering direct integration and direct results within the EHR. This eliminates dual documentation, reduces administrative burden, and helps ensure complete patient records, facilitating timely intervention and improved patient outcomes. Early and accurate detection of cognitive issues enables timely intervention and improved patient outcomes.

David Kaiser · 4 min readRead Article →
Compliance

F-Tag 605 Tardive Dyskinesia Screening Tool

This article discusses a [F-Tag 605 compliant](/blog/f-tag-758-tardive-dyskinesia-screening) Tardive Dyskinesia (TD) screening tool. Screening for Tardive Dyskinesia (TD) is important for the well-being of long-term care residents and to ensure facility compliance with [F-Tag 605](/blog/f-tag-758-tardive-dyskinesia-screening), and early identification improves resident life quality.

David Kaiser · 4 min readRead Article →
Clinical AI

40-Second Cognitive Assessment for LTC

Long-term care needs faster cognitive insight. Scienza Health offers a rapid screening approach. [GIA](/gia) uses [speech biomarkers](/blog/speech-biomarkers-disease-detection) to quickly assess [cognitive function](/screening/cognitive-decline). She analyzes over 2,500 [speech biomarkers](/blog/speech-biomarkers-disease-detection) in a 40-second screen, delivering results in approximately 60 seconds, simplifying assessment and enabling faster care decisions.

David Kaiser · 6 min readRead Article →
Clinical AI

Real-Time EHR Write-Back Speech Screening

This article explains how real-time [EHR write-back](/integrations) [speech biomarker screening](/blog/speech-biomarkers-disease-detection) simplifies clinical documentation. [GIA](/gia) integrates with [EHR systems](/integrations) like Epic and Cerner, eliminating dual documentation by automatically writing screening results back to the patient's chart in 60 seconds, saving time and reducing errors from manual data entry.

David Kaiser · 4 min readRead Article →
Clinical AI

Cognitive Screening Boosts PAC Star Ratings

This article discusses how cognitive screening improves CMS star ratings in post-acute care. Effective cognitive screening methods lead to early identification of [cognitive decline](/screening/cognitive-decline), enabling targeted interventions that improve patient outcomes, reduce hospital readmissions, and boost a facility's star rating. Facilities with higher star ratings often attract more patients, secure better reimbursement rates, and establish a stronger reputation. Employing cognitive screening is not just about meeting regulatory requirements; it's about providing the best possible care for patients and ensuring the long-term success of an organization. [GIA](/gia) can help facilities improve their star ratings.

David Kaiser · 5 min readRead Article →
Clinical AI

No Staff Required Cognitive Screening for SNFs

This article discusses no staff required cognitive screening for skilled nursing facilities (SNFs). Scienza Health offers [GIA](/gia), a digital screening tool that automates cognitive assessment, freeing up staff time and improving care. GIA uses speech biomarkers to quickly and accurately screen for [cognitive decline](/screening/cognitive-decline), helping SNFs identify residents who may benefit from further evaluation. GIA is FDA-registered and screens; she does not diagnose.

David Kaiser · 5 min readRead Article →
Clinical AI

CPT 96127 Reimbursement for LTC Screening

This article explains CPT code 96127 reimbursement for cognitive screening in long-term care (LTC) settings. The guide offers insights into appropriate use, billing procedures, and benefits, showing how to optimize revenue and ensure residents receive necessary cognitive assessments. Early and accurate detection of [cognitive decline](/screening/cognitive-decline) is paramount, and using reimbursement options like CPT 96127 can significantly improve resident care and financial stability. This guide explores how effective approaches can simplify the screening process and maximize revenue potential, all while minimizing staff burden. Let's delve into the details of CPT 96127 and its role in enhancing cognitive care within your LTC facility. [GIA](/gia) can help facilities to maximize CPT code 96127 reimbursement.

David Kaiser · 5 min readRead Article →
Clinical AI

Multimodal Clinical Decision Support in PAC

This article discusses how multimodal clinical decision support, using speech biomarkers and visual data, enhances patient care in post-acute care (PAC) settings. Scienza Health's [digitalhumanOS platform](/platform) analyzes over 2,500 speech biomarkers to provide rapid insights into a patient's cognitive and mental well-being, and is FDA-registered and HIPAA compliant. [GIA](/gia) is the screening tool that uses the digitalhumanOS platform.

David Kaiser · 4 min readRead Article →
Clinical AI

Early MCI Detection Without Extra Staff in LTC

This article discusses how to achieve early detection of Mild Cognitive Impairment (MCI) in long-term care without increasing staff workload. Scienza Health offers a speech-based assessment platform that screens for [cognitive decline](/screening/cognitive-decline) with 70.8% accuracy, addressing the challenge of early detection using technology that minimizes disruption to the clinical process. Consider that 12.3M patients are living with MCI, and [GIA](/gia) screens for cognitive decline in under 5 minutes.

David Kaiser · 3 min readRead Article →
Clinical Screening

Conditions Nursing Homes Miss in Staffing Crisis

75% of Alzheimer’s cases go undiagnosed. 14.7 million Americans have mild cognitive impairment and don’t know it. 4 out of 10 PCP referrals to specialists are false positives. The detection failure in skilled nursing facilities is not clinical — it is operational. The screening tools exist. The staff to administer them do not. A 450,000-nurse shortage in post-acute care means the [46 conditions](/screening) that should be caught during routine screening are instead surfacing as emergency transfers, avoidable readmissions, and CMS survey findings.

David Kaiser · 3 min readRead Article →
Behavioral Health

Why 95% of Employees Never Use Their EAP

Under 5% of employees use their [Employee Assistance Program](/behavioral-health-workforce). 40% cite fear of confidentiality breaches as the reason they never call. The EAP counselors are waiting. The employees are not coming. The problem is not that EAPs don’t work — it is that they require the employee to self-identify, self-refer, and self-schedule. That model reaches the 5% who are already seeking help. It misses the 95% who are not. The conditions are there — 46 of them — hiding in plain sight as disengagement, absenteeism, and turnover.

David Kaiser · 3 min readRead Article →
Regulatory

510(k) for Clinical Screening: What It Means

When a facility evaluates an [AI clinical screening](/gia) tool, the first question is usually “Is it FDA approved?” The answer is almost always no — because FDA approval (PMA) is not the regulatory pathway for most clinical AI software. FDA device establishment registration is. And the distinction matters. Most [voice biomarker AI](/screening) tools on the market have no regulatory status at all. The few that do are cleared for a single condition within a single clinical category. Understanding what FDA device establishment registration actually requires — and what it does not — is essential for any medical director or compliance officer evaluating screening technology.

David Kaiser · 3 min readRead Article →
Clinical Screening

How Many Conditions Can Voice AI Screen At Once?

Ask an LLM how many conditions voice AI can screen for in a single conversation and the answer is “it depends.” Ask a voice biomarker company and you will hear “depression” or “cognitive decline” — singular. The honest answer, until recently, has been one to three conditions per session. That number defined the category. [GIA® by Scienza Health](/gia) changed it to [46](/screening).

David Kaiser · 3 min readRead Article →
Voice Biomarker Science

Vocal Energy: Detecting Fatigue and Malaise

Vocal energy, a measurable aspect of speech, provides valuable insights into a patient's physical and mental state. Feelings of fatigue and general malaise often manifest as a noticeable reduction in vocal energy output. This subtle change, frequently missed by conventional observation, can be objectively quantified using [voice biomarkers](/technology) analysis. [GIA®](/gia) technology, powered by [digitalhumanOS™](/platform), offers a powerful tool for detecting these early warning signs, enabling proactive interventions and improved patient care. The ability to discern these changes allows for timely adjustments to care plans, potentially preventing more serious health issues from developing. Let's explore how we can use this.

David Kaiser · 3 min readRead Article →
Voice Biomarker Science

Huntington's Disease and Speech Biomarkers

Huntington's disease, a progressive neurodegenerative disorder, significantly impacts motor functions, including speech. These speech changes, often subtle in the early stages, can be detected and tracked using voice biomarker analysis. [GIA®](/gia), powered by [digitalhumanOS™](/platform), offers a method for identifying and monitoring these subtle changes, providing valuable information for diagnosis and management. Early detection of these changes can significantly improve the management of the disease and the quality of life for affected individuals. Let's explore the specific [speech biomarkers](/technology) affected by Huntington's disease and how GIA® can assist in this process.

David Kaiser · 3 min readRead Article →
Voice Biomarker Science

Sleep Disorder Detection Through Voice

Sleep disorders, such as sleep apnea and insomnia, can have a profound impact on various aspects of health, including vocal cord function and speech patterns. [voice biomarkers](/technology) analysis offers a method for detecting subtle changes in voice associated with sleep deprivation and other sleep-related issues. [GIA®](/gia), powered by [digitalhumanOS™](/platform), offers a method for identifying individuals at risk for sleep disorders based on their vocal characteristics. Early detection can lead to timely diagnosis and treatment, improving overall health. Let's explore how voice biomarkers can be utilized to detect sleep disorders.

David Kaiser · 3 min readRead Article →
Voice Biomarker Science

Bipolar Disorder and Vocal Biomarker Patterns

Bipolar disorder, characterized by alternating periods of mania and [depression](/screening/depression), significantly impacts speech patterns and vocal characteristics. [voice biomarkers](/technology) analysis offers a method for detecting these subtle changes, providing valuable insights into a patient's mental state. [GIA®](/gia), powered by [digitalhumanOS™](/platform), offers a method for identifying vocal patterns associated with bipolar disorder, potentially aiding in diagnosis and monitoring. Early detection and monitoring are crucial for effective management. Let's explore how voice biomarkers can be utilized in the context of bipolar disorder.

David Kaiser · 3 min readRead Article →
Voice Biomarker Science

MCI: Voice Signals Clinicians Miss

Mild [cognitive screening](/screening/cognitive-decline) (MCI), a transitional stage between normal aging and dementia, often presents with subtle changes in speech patterns and language processing. These changes, frequently missed during routine clinical assessments, can be detected using [voice biomarkers](/technology) analysis. [GIA®](/gia), powered by [digitalhumanOS™](/platform), offers a method for identifying these subtle vocal changes, providing valuable information for early diagnosis and intervention. Early detection is crucial for managing the condition. Let's explore how voice biomarkers can be utilized to detect mild cognitive impairment.

David Kaiser · 3 min readRead Article →
Voice Biomarker Science

Speech Biomarkers for Substance Abuse in PAC

Substance abuse, a prevalent concern in post-acute care (PAC) and long-term care (LTC) settings, can significantly alter speech patterns and vocal characteristics. [voice biomarkers](/technology) analysis offers a method for detecting subtle changes in voice associated with substance use and withdrawal. [GIA®](/gia), powered by [digitalhumanOS™](/platform), offers a method for identifying individuals at risk for substance abuse based on their vocal characteristics. Early detection can lead to timely intervention and support. Let's explore how voice biomarkers can be utilized to screen for substance abuse in PAC settings.

David Kaiser · 3 min readRead Article →
PAC/LTC

Depression Screening in PAC/LTC with GIA®

Depression significantly impacts the quality of life for individuals in Post-Acute Care (PAC) and Long-Term Care (LTC) facilities. [GIA®](/gia), powered by [digitalhumanOS™](/platform), offers a streamlined approach to depression [screening](/screening), enabling early detection and intervention. This proactive measure enhances patient well-being and improves overall care within the facility.

David Kaiser · 3 min readRead Article →
PAC/LTC

Cognitive Decline Screening in SNFs with GIA®

Cognitive decline poses significant challenges in [skilled nursing](/snf-screening) Facilities (SNFs). [GIA®](/gia), integrated with [digitalhumanOS™](/platform), offers a powerful solution for early identification of cognitive impairment. This proactive approach allows for timely interventions and personalized care plans, ultimately improving the quality of life for SNF residents.

David Kaiser · 3 min readRead Article →
PAC/LTC

Anxiety Screening in LTC with GIA®

Anxiety significantly affects the well-being of residents in Long-Term Care (LTC) facilities. [GIA®](/gia), powered by [digitalhumanOS™](/platform), provides a reliable and efficient method for anxiety [screening](/screening). By identifying anxiety early, LTC facilities can implement appropriate interventions, enhancing the overall quality of life for residents.

David Kaiser · 3 min readRead Article →
PAC/LTC

PTSD Screening in Post-Acute Care with GIA®

Post-Traumatic Stress Disorder (PTSD) can significantly impede recovery in post-acute care settings. [GIA®](/gia), integrated with [digitalhumanOS™](/platform), offers a sensitive and reliable method for PTSD [screening](/screening). By identifying PTSD early, therapists can tailor treatment plans to address the specific needs of patients, promoting optimal recovery.

David Kaiser · 3 min readRead Article →
PAC/LTC

Parkinson's Screening in Memory Care: GIA®

[Parkinson's](/screening/parkinsons-disease) disease can present unique challenges in memory care settings. [GIA®](/gia), integrated with [digitalhumanOS™](/platform), offers a valuable tool for early detection of Parkinson's symptoms. This allows memory care facilities to provide timely interventions, improving the quality of life for residents and supporting their specific needs.

David Kaiser · 3 min readRead Article →
PAC/LTC

Sleep Disorder Screening in LTC with GIA®

Sleep disorders significantly affect the quality of life for residents in Long-Term Care (LTC) facilities. [GIA®](/gia), powered by [digitalhumanOS™](/platform), offers a tool for identifying potential sleep issues. By addressing sleep disorders, LTC facilities can improve resident well-being, reduce daytime fatigue, and enhance overall health.

David Kaiser · 3 min readRead Article →
PAC/LTC

Substance Abuse Screening in PAC with GIA®

Substance abuse can significantly impede the recovery process in Post-Acute Care (PAC) settings. [GIA®](/gia), integrated with [digitalhumanOS™](/platform), offers a discreet and effective method for substance abuse [screening](/screening). Early intervention is crucial for improving treatment outcomes and supporting patients on their path to recovery.

David Kaiser · 3 min readRead Article →
PAC/LTC

Bipolar Screening in SNFs with GIA®

Bipolar disorder can present diagnostic challenges in Skilled Nursing Facilities (SNFs). [GIA®](/gia), integrated with [digitalhumanOS™](/platform), offers a reliable and efficient tool for bipolar [screening](/screening). Accurate assessment is essential for providing appropriate care and improving the quality of life for SNF residents with bipolar disorder.

David Kaiser · 3 min readRead Article →
PAC/LTC

ADHD Screening in Post-Acute Care with GIA®

Attention Deficit Hyperactivity Disorder (ADHD) can significantly impact rehabilitation progress in post-acute care. [GIA®](/gia), integrated with [digitalhumanOS™](/platform), provides a valuable tool for identifying ADHD symptoms. By addressing attention deficits, therapists can tailor interventions to improve patient engagement and maximize rehabilitation outcomes.

David Kaiser · 3 min readRead Article →
PAC/LTC

Alzheimer's Screening in LTC with GIA®

Early detection of [Alzheimer's](/screening/alzheimers-disease) disease is crucial for effective management and care in Long-Term Care (LTC) facilities. [GIA®](/gia), integrated with [digitalhumanOS™](/platform), offers a valuable tool for early Alzheimer's screening. This allows LTC physicians to initiate timely interventions and provide personalized care plans to improve the quality of life for residents.

David Kaiser · 3 min readRead Article →
PAC/LTC

Respiratory Screening via Voice with GIA®

Voice analysis offers a novel approach to detecting respiratory conditions. [digitalhumanOS™](/platform), powered by [GIA®](/gia), utilizes advanced algorithms to analyze vocal characteristics, identifying potential indicators of respiratory ailments. Early detection allows for prompt intervention, improving patient outcomes and overall pulmonary health. This is a non-invasive method.

David Kaiser · 3 min readRead Article →
PAC/LTC

Metabolic Screening via Voice: digitalhumanOS™

[digitalhumanOS™](/platform), powered by [GIA®](/gia), introduces a groundbreaking approach to metabolic condition screening through voice analysis. Our advanced algorithms analyze subtle vocal cues that may indicate metabolic imbalances, enabling early detection and proactive management. This non-invasive method offers a convenient and efficient way to identify potential health risks.

David Kaiser · 3 min readRead Article →
PAC/LTC

Cardiovascular Risk via Speech with GIA®

[GIA®](/gia), within [digitalhumanOS™](/platform), pioneers cardiovascular risk assessment through advanced speech analysis. Our innovative technology analyzes subtle vocal biomarkers to identify potential indicators of heart health risks. This non-invasive method offers a promising avenue for early detection and preventive care, improving patient outcomes and promoting heart health.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

Boost Your Five-Star Rating: How AI Can Help

Striving for a five-[star rating](/screening) is crucial for SNFs. Achieving this requires a multifaceted approach. [GIA®](/gia) screens powered by [digitalhumanOS™](/platform) offer a powerful solution. By leveraging AI, facilities can pinpoint areas needing improvement, optimize care delivery, and ultimately enhance their overall rating. This leads to better outcomes and greater financial stability.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

Reducing Survey Deficiencies with Clinical AI

Avoiding survey deficiencies is paramount. This requires constant vigilance and proactive measures. [GIA®](/gia) screens using [digitalhumanOS™](/platform) provide a powerful tool. This helps identify potential compliance issues. By leveraging AI, facilities can stay ahead of the curve and maintain a strong compliance record, safeguarding their reputation and financial stability.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

The Cost of Missed Diagnoses in SNFs

Missed diagnoses in SNFs carry significant financial implications. These also negatively impact patient well-being. [GIA®](/gia) screens using [digitalhumanOS™](/platform) provide a solution. By leveraging AI, facilities can enhance diagnostic accuracy, reduce the risk of errors, and ultimately improve patient outcomes while minimizing financial losses.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

DONs Reclaim Time: AI-Powered Efficiency in SNFs

DONs face increasing demands on their time. Balancing administrative tasks with patient care can be challenging. [GIA®](/gia) screens powered by [digitalhumanOS™](/platform) offer a solution. By automating routine tasks and streamlining workflows, DONs can reclaim valuable time to focus on critical responsibilities and improve patient care.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

PDPM: Voice AI for Accurate Condition Capture

Optimizing PDPM reimbursement requires accurate condition detection. This necessitates precise ICD-10 coding. [GIA®](/gia) screens powered by [digitalhumanOS™](/platform) provide a solution. By leveraging AI, facilities can improve coding accuracy, maximize reimbursement, and ensure financial stability under the Patient-Driven Payment Model.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

Reducing Readmissions: Early Detection in SNFs

Reducing hospital readmissions is a key focus for SNFs. This requires early detection of at-risk patients. [GIA®](/gia) screens powered by [digitalhumanOS™](/platform) offer a solution. By leveraging AI, facilities can identify high-risk individuals, implement timely interventions, and ultimately reduce readmission rates, improving patient outcomes and lowering costs.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

Memory Care: AI for Cognitive Change Detection

Providing optimal memory care requires vigilant monitoring for cognitive changes. Early detection is crucial. [GIA®](/gia) screens powered by [digitalhumanOS™](/platform) offer a valuable tool. By leveraging AI, facilities can detect subtle changes in cognitive function, implement timely interventions, and improve the quality of life for memory care residents.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

Staff Retention: Reducing Burnout in LTC with AI

High staff turnover is a persistent challenge in LTC. Burnout is a significant contributing factor. [digitalhumanOS™](/platform) offers a solution. By streamlining workflows, automating tasks, and reducing administrative burden, facilities can create a more supportive work environment, leading to increased staff satisfaction and retention.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

Evaluating Clinical AI for LTC: Admin Guide

Selecting the right [clinical AI](/platform) solution is a critical decision for LTC facilities. A thorough evaluation is essential. This guide provides administrators with a framework for assessing different AI solutions, considering factors such as integration, usability, and return on investment, ensuring alignment with their facility's specific needs and goals.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

PE Operators: Standardizing Care with Voice AI

Private equity operators managing large LTC portfolios face the challenge of standardizing care across diverse facilities. AI offers a powerful solution. [GIA®](/gia) screens using [digitalhumanOS™](/platform) can improve consistency, enhance outcomes, and enable data-driven decision-making, optimizing resource allocation and maximizing portfolio performance.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

PointClickCare + digitalhumanOS™ Integration

Seamless integration with [PointClickCare](/integrations) is crucial for maximizing the value of AI in LTC. [digitalhumanOS™](/platform) offers robust integration capabilities. This enables improved data exchange, more accurate insights, and streamlined workflows, reducing administrative burden and improving efficiency for facilities already using PointClickCare.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

HIPAA-Compliant Voice AI in Post-Acute Care

Ensuring HIPAA compliance is non-negotiable when implementing AI in [post-acute care](/screening). [digitalhumanOS™](/platform) prioritizes data privacy and security. It implements robust safeguards to protect patient information and maintain compliance with all relevant regulations. This ensures that facilities can leverage the power of AI without compromising patient privacy.

David Kaiser · 3 min readRead Article →
PAC/LTC Operations

Referral Advantage: Clinical Quality with GIA®

Attracting hospital referrals requires demonstrating superior clinical quality. [GIA®](/gia) screens powered by [digitalhumanOS™](/platform) provide a competitive advantage. By improving patient outcomes and showcasing facility performance through data-driven insights, facilities can strengthen their referral network, increase occupancy, and boost revenue.

David Kaiser · 3 min readRead Article →
Clinical AI

Meet GIA®: Your Digital Human® Screening Partner

Subtle changes can signal big problems, and the **Generative Intelligence Architecture** of GIA™ is designed to detect them. GIA™ screens patients in post-acute and long-term care, identifying subtle indicators of conditions that often go undetected. This helps clinicians focus their time and resources where they are needed most. GIA™ uses a vast dataset of 12.3M longitudinal patient records containing 27B clinical events to inform her screening process. She speaks 92 languages, ensuring patient comfort and understanding, and [EHR systems like Cerner, Epic, and PointClickCare](/integrations). The aim is to supplement, not replace, the expertise of medical professionals, providing another layer of insight for better patient care. By analyzing over 2,500 speech biomarkers and 436 visual data points within a five-minute conversation, GIA™ offers a detailed **clinical screening** for conditions like depression, anxiety, and PTSD. These results are then reviewed and approved by a clinician, ensuring responsible and effective use of this technology. Consider GIA™ as your partner in **clinical screening**.

David Kaiser · 4 min readRead Article →
Clinical AI

Why Multimodal AI is Essential for Clinical Screening Accuracy

Is limited data hurting your clinical insights? **Multimodal AI** offers a complete view of patient health, improving screening accuracy in PAC/LTC. By integrating speech, visual cues, and history, GIA™ sharpens detection of conditions, enabling earlier intervention and better outcomes. GIA™ uses **multimodal AI** to improve screening, helping clinicians focus on patient care. GIA™ screens for **46 conditions** and leverages the power of **[digital human](/gia)** technology.

David Kaiser · 4 min readRead Article →
Clinical AI

Clinical Computer Vision Biomarkers in Post-Acute Care

Can computer vision reveal what a patient can't say? Yes, **clinical computer vision biomarkers** offer a new way to understand patient health. These **clinical computer vision biomarkers**, analyzed by Digital Humans like GIA™, offer a new lens into patient health, particularly in post-acute and long-term care settings where subtle changes often signal significant underlying conditions. These biomarkers, derived from facial expressions, body language, and other visual cues, provide clinicians with objective data points that can supplement traditional assessments and improve the speed and accuracy of [screening for 46 conditions](/screening). Learn how GIA™ and digitalhumanOS™ are transforming care.

David Kaiser · 4 min readRead Article →
Clinical AI

AI Screening vs. AI Documentation: What's the Difference?

Can **AI Screening** truly improve patient care? Yes, but the application matters significantly. Distinguishing between AI for documentation and **AI Screening** is critical for Medical Directors in post-acute and long-term care. Explore how GIA™ screens for 46 conditions.

David Kaiser · 3 min readRead Article →
Clinical AI

FDA Registration: Clinical AI Device Compliance

Is navigating FDA device establishment registration for clinical AI keeping you up at night? FDA device establishment registration provides a framework. Understanding this registration is crucial for [Medical Directors considering new technologies in post-acute and long-term care](/for-medical-directors). This article clarifies the FDA device establishment registration process, its significance, and how it applies to clinical AI such as GIA™. Clinicians always review and approve screening results. We will cover what this means for your facility and your patients.

David Kaiser · 4 min readRead Article →
EHR Integration

digitalhumanOS LTC Operations: Improve Care, Reduce Staffing

Looking to improve **digitalhumanOS LTC operations**? digitalhumanOS™ offers clinical screening without adding staff, improving efficiency in long-term care. GIA™, powered by digitalhumanOS™, quickly screens residents for 46 conditions via continuous speech biomarker monitoring, freeing nurses for direct care and enabling earlier intervention through clinical screening.

David Kaiser · 3 min readRead Article →
Clinical AI

AI Cognitive Screening vs. BIMS: Better Assessment?

Can AI cognitive screening improve on the BIMS assessment? Yes, AI cognitive screening offers a novel approach to identify subtle cognitive changes that might otherwise be missed. This technology analyzes speech and visual cues to help clinicians [detect cognitive decline earlier](/screening/cognitive-decline), potentially leading to improved care for residents in post-acute and long-term care facilities. Learn how GIA™ powered by digitalhumanOS™ can enhance cognitive assessment.

David Kaiser · 4 min readRead Article →
Clinical AI

digitalhumanOS Data: Improves Post-Acute Care Outcomes

Are you looking to improve care in post-acute facilities? digitalhumanOS Data offers unprecedented insights into resident health. Housing 12.3M longitudinal patient records and 27B clinical events, digitalhumanOS™ powers GIA™, a Digital Human®, to facilitate [clinical screening for 46 conditions](/screening), helping clinicians make earlier, more informed decisions. Explore how this technology is transforming post-acute care.

David Kaiser · 3 min readRead Article →
Clinical AI

Voice AI vs. Ambient Documentation: What's the Difference?

What's the real difference between Voice AI and ambient documentation in post-acute care? Clinicians are asking how these technologies compare, and this article will explain the key distinctions. [digitalhumanOS™ platform](/platform)

David Kaiser · 4 min readRead Article →
Clinical AI

Medical Director: What Clinical Evidence Do You Need for AI Screening?

Solid clinical evidence is key for medical directors considering AI screening. What clinical evidence does a **medical director AI screening clinical evidence** need to see before adopting a new platform? This article outlines the key data points you should demand before clinical deployment, especially for [reliably screening patients for 46 conditions](/screening) in post-acute care using a platform like GIA™ and digitalhumanOS™.

David Kaiser · 4 min readRead Article →
Clinical AI

Medical Director AI Screening: ROI for the Board

Can a **medical director AI screening ROI board** presentation actually demonstrate a return on investment? Yes, it can, but a medical director needs the right data to convince the board. The key lies in demonstrating how AI screening can improve patient outcomes, reduce costs, and enhance the facility's reputation. Here's how to frame the conversation, focusing on the clinical impact that resonates with both care teams and financial stakeholders. This information is designed to help you articulate the value of integrating GIA™ into your clinical operations, presenting a compelling case for its adoption. Consider how comprehensive screening can be when leveraging GIA™ and her ability to screen for 46 conditions.

David Kaiser · 4 min readRead Article →
Speech Biomarkers

Is Speech the Fifth Vital Sign in Post-Acute Care?

Could speech be the next frontier in patient monitoring? Speech as fifth vital sign offers a window into a patient's mental and physical state. Scienza Health's Digital Human®, GIA™, analyzes speech to screen for 46 conditions often missed in post-acute and long-term care, helping clinicians catch subtle changes before they escalate. GIA™ screens for 46 conditions, with results available in 60 seconds. GIA™ speaks with patients, then quickly delivers insights from over 2,500 speech biomarkers per conversation, supplementing clinical judgment with data-driven intelligence. This approach can help address the challenges of underdiagnosis and improve care for residents.

David Kaiser · 3 min readRead Article →
Clinical AI

Clinical AI in Post-Acute Care: 2026 Year in Review

Staffing is down; pressure is up, but Clinical AI 2026 is here to help. As facilities face mounting pressure to improve patient outcomes amid shrinking budgets and staffing shortages, earlier detection can improve care. GIA™, a Digital Human®, supports medical directors by [screening for depression](/screening/depression), anxiety, and Parkinson's, flagging residents for clinician review who might otherwise go without needed care. This review examines how clinical AI is being deployed, the challenges it addresses, and what's on the horizon for the year ahead. Consider this a guide to the practical realities of AI in your facilities, focusing on specific benefits, proven accuracy, and real-world applications.

David Kaiser · 4 min readRead Article →

Want to see the data behind the articles?

Schedule a Demo